Mehmet Altan

7.2k total citations
121 papers, 2.5k citations indexed

About

Mehmet Altan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Mehmet Altan has authored 121 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 20 papers in Immunology. Recurrent topics in Mehmet Altan's work include Cancer Immunotherapy and Biomarkers (74 papers), Lung Cancer Treatments and Mutations (41 papers) and Lung Cancer Research Studies (17 papers). Mehmet Altan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (74 papers), Lung Cancer Treatments and Mutations (41 papers) and Lung Cancer Research Studies (17 papers). Mehmet Altan collaborates with scholars based in United States, China and Greece. Mehmet Altan's co-authors include David L. Rimm, Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Roy S. Herbst, Yinghong Wang, Maria Toki, Hamzah Abu‐Sbeih, Mark M. Awad, Patricia Gaule and Scott Gettinger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Mehmet Altan

114 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mehmet Altan United States 24 2.1k 885 559 376 364 121 2.5k
Justine V. Cohen United States 22 2.4k 1.2× 838 0.9× 583 1.0× 373 1.0× 516 1.4× 96 3.4k
Leila Khoja United Kingdom 20 1.7k 0.8× 612 0.7× 403 0.7× 155 0.4× 416 1.1× 50 2.1k
Alejandro Navarro Spain 19 2.0k 1.0× 1.3k 1.5× 304 0.5× 613 1.6× 669 1.8× 110 2.6k
Claire F. Friedman United States 21 1.6k 0.8× 463 0.5× 539 1.0× 196 0.5× 280 0.8× 80 2.1k
Hira Rizvi United States 23 2.9k 1.4× 1.7k 1.9× 508 0.9× 280 0.7× 683 1.9× 64 3.5k
Ryan D. Gentzler United States 20 2.1k 1.0× 1.4k 1.6× 426 0.8× 113 0.3× 285 0.8× 86 2.5k
Kelly Olino United States 23 1.5k 0.7× 413 0.5× 499 0.9× 389 1.0× 470 1.3× 75 2.2k
Asim Amin United States 27 2.6k 1.3× 1.1k 1.2× 1.1k 2.0× 346 0.9× 905 2.5× 73 3.4k
Sofiya Latifyan Switzerland 8 1.4k 0.7× 389 0.4× 540 1.0× 149 0.4× 290 0.8× 24 1.9k
Akin Atmaca Germany 24 2.2k 1.0× 1.4k 1.6× 505 0.9× 580 1.5× 845 2.3× 61 3.3k

Countries citing papers authored by Mehmet Altan

Since Specialization
Citations

This map shows the geographic impact of Mehmet Altan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehmet Altan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehmet Altan more than expected).

Fields of papers citing papers by Mehmet Altan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehmet Altan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehmet Altan. The network helps show where Mehmet Altan may publish in the future.

Co-authorship network of co-authors of Mehmet Altan

This figure shows the co-authorship network connecting the top 25 collaborators of Mehmet Altan. A scholar is included among the top collaborators of Mehmet Altan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehmet Altan. Mehmet Altan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Williams, Loretta A., et al.. (2025). Patient‐Reported Outcomes for Patients With Metastatic NSCLC Treated at an Academic Medical Center, 2017–2021. Cancer Medicine. 14(15). e71111–e71111. 1 indexed citations
3.
Altan, Mehmet, Dawen Sui, Cai Xu, et al.. (2025). PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021. PubMed. 8(2). 161–171. 1 indexed citations
4.
Shroff, Girish S., et al.. (2024). Drug-induced Lung Disease in the Oncology Patient. Clinics in Chest Medicine. 45(2). 325–337. 1 indexed citations
5.
Lu, Eric, Malek Shatila, Anusha Shirwaikar Thomas, et al.. (2024). The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity. American Journal of Clinical Oncology. 48(3). 136–141. 1 indexed citations
6.
Faiz, Saadia A., et al.. (2024). Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies. SHILAP Revista de lepidopterología. 7(4). 272–282. 2 indexed citations
7.
8.
López-Olivo, María A., Gabrielle F. Duhon, Mehmet Altan, et al.. (2023). Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study. Cancers. 15(10). 2690–2690. 4 indexed citations
9.
Xu, Ting, Ajay Sheshadri, Anita Deswal, et al.. (2023). Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e54–e55. 1 indexed citations
10.
Altan, Mehmet, Denái R. Milton, Bülent Yılmaz, et al.. (2023). Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer. Cancer. 129(17). 2685–2693. 6 indexed citations
11.
Singhi, Eric K., Frank E. Mott, Cheuk Hong Leung, et al.. (2023). Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer. Oncology Letters. 25(6). 262–262. 1 indexed citations
12.
Liu, Cynthia, Dongfeng Tan, Mehmet Altan, et al.. (2022). Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. Journal of Cancer Research and Clinical Oncology. 149(8). 5429–5436. 2 indexed citations
13.
Shroff, Girish S., Chad D. Strange, Jitesh Ahuja, et al.. (2022). Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer. Radiographics. 42(7). 1956–1974. 8 indexed citations
14.
Patel, Anisha B., et al.. (2021). Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy. Clinical Lung Cancer. 22(3). 195–200.e1. 9 indexed citations
15.
Yang, Eddy S., Éric Deutsch, Mehmet Altan, et al.. (2021). A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Radiotherapy and Oncology. 157. 203–209. 19 indexed citations
16.
Sepesi, Boris, Tina Cascone, Stephen G. Chun, Mehmet Altan, & Xiuning Le. (2020). Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer. Surgical Oncology Clinics of North America. 29(4). 555–569. 8 indexed citations
17.
Alessi, Joao V., Biagio Ricciuti, Fangxin Hong, et al.. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for ImmunoTherapy of Cancer. 8(2). e001007–e001007. 40 indexed citations
18.
Altan, Mehmet, Vasiliki Pelekanou, Kurt A. Schalper, et al.. (2017). B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research. 23(17). 5202–5209. 108 indexed citations
19.
Schalper, Kurt A., Daniel Carvajal‐Hausdorf, Joseph McLaughlin, et al.. (2016). Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research. 23(2). 370–378. 160 indexed citations
20.
Pusztai, Lajos, Stacy L. Moulder, Mehmet Altan, et al.. (2014). Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer. Clinical Cancer Research. 20(20). 5265–5271. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justine V. Cohen Breakdown of academic impact, for papers by Leila Khoja Breakdown of academic impact, for papers by Alejandro Navarro Breakdown of academic impact, for papers by Claire F. Friedman Breakdown of academic impact, for papers by Hira Rizvi Breakdown of academic impact, for papers by Ryan D. Gentzler Breakdown of academic impact, for papers by Kelly Olino Breakdown of academic impact, for papers by Asim Amin Breakdown of academic impact, for papers by Sofiya Latifyan Breakdown of academic impact, for papers by Akin Atmaca
Rankless by CCL
2026